VF
ECYT

Virtu Financial’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Virtu Financial’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-43,760
Closed -$398K – 2772
2018
Q1 		$398K Buy
43,760
+26,936
+160% +$149K 0.02% 844
2017
Q4 		$72K Buy
+16,824
New +$80.2K ﹤0.01% 2000

Other funds holding ECYT

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial's ECYT Position: Q2 2018 in Review

Virtu Financial sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 43,760 shares — an estimated $398K sold.

Virtu Financial first reported a position in ECYT in Q4 2017 and held it in 2 quarters. The position peaked at $398K in Q1 2018. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

  • Virtu Financial reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Virtu Financial sold 43,760 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $398K.
  • Virtu Financial first reported a position in Endocyte, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Virtu Financial's Endocyte, Inc. Common Stock position peaked at $398K in Q1 2018.
  • 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Virtu Financial's 13F filing for Q2 2018, filed 30 Jul 2018.